MGMT and glioblastoma: Its incidence rate is 3–5 cases per 100 000 people each year,1,2 with a median overall survival (OS) of around 15 months.1,2 The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter is a crucial prognostic factor in patients with GBM.